In re Vaxart, Inc. Securities Litigation

  1. July 08, 2025

    Vaxart Investors Can Pursue Suit Over COVID Vax Claims

    A California federal judge declined to grant an early win to the onetime controlling shareholder of Vaxart in an investor suit alleging it dumped stock at inflated prices following deceptive headlines about the biotechnology company's ability to produce a COVID-19 vaccine.

  2. December 18, 2024

    Vaxart Investors Win Class Cert. Over COVID Shot On 2nd Try

    A California federal judge has certified a class of Vaxart investors accusing the biotechnology company's onetime controlling shareholder of dumping stock at inflated prices following deceptive headlines about a COVID-19 vaccine, saying the investors' revised motion fixes issues of predominance and the damages model.

  3. December 09, 2024

    Akin Gump 'Totally Messed Up' With Texts, Vaxart Judge Says

    A California federal judge asked by Vaxart investors to impose sanctions over a hedge fund's deleted text messages in a case claiming Vaxart inflated its stock price with deceptive headlines about a COVID-19 vaccine said Monday that the fund's lawyers at Akin Gump "totally, totally messed up."

  4. April 30, 2024

    Vaxart Investors Want Sanctions Over Deleted Texts

    A group of Vaxart investors asked a California federal judge to issue sanctions against Armistice Capital LLC, which previously controlled Vaxart and allegedly sold $267 million worth of its Vaxart shares at inflated prices, saying the hedge fund and its executives purposely deleted text messages integral to the investors' claims.

  5. August 22, 2022

    Vaxart Investors Seek Initial OK Of $12M Deal In Fraud Suit

    A proposed class of investors in Vaxart has urged a California federal court to give its initial OK to a $12 million settlement with the biotechnology company over allegations it pumped its stock price with deceptive headlines about a COVID-19 vaccine, arguing that it's a favorable outcome for investors.

  6. December 22, 2021

    Vaxart Can't Ditch Claims Co. Lied To Investors About Vaccine

    A California federal judge kept alive a proposed securities class action Wednesday claiming the biotechnology company Vaxart pumped up its stock price with deceptive headlines about a COVID-19 vaccine, but tossed with leave to amend claims against a hedge fund that sold shares in the wake of Vaxart's statements.

  7. September 30, 2021

    Vaxart Buried Investors In 'Avalanche Of B.S.,' Judge Says

    U.S. District Judge Vince Chhabria appeared skeptical Thursday of Vaxart's efforts to ditch a proposed securities class action claiming the biotechnology company artificially inflated its stock price with an allegedly deceptive headline about producing a COVID-19 vaccine candidate, saying the defendants "buried the investors in an avalanche of B.S."

  8. May 13, 2021

    Vaxart Investors Can Tweak Stock Claims Over COVID Vaccine

    A group of investors suing Vaxart Inc. can amend their complaint to more clearly allege that the company artificially inflated its stock price through a press release with a deceptive headline about being a COVID-19 vaccine candidate, a California federal judge ruled on Thursday.

  9. March 15, 2021

    Biotech Co. Says It Never Lied About Its COVID Vaccine Work

    Vaxart Inc. asked a California federal judge Friday to dismiss allegations that it misled investors about the prospects of its COVID-19 vaccine candidate, saying the securities suit is "premised on statements Vaxart never made."

  10. December 09, 2020

    Hagens Berman To Lead Investors' COVID-19 Vaccine Suit

    A California federal judge on Wednesday appointed Hagens Berman Sobol Shapiro LLP lead counsel in a proposed class action filed by investors alleging San Francisco-based biotechnology company Vaxart Inc. lied about its COVID-19 vaccine candidate.